Downsizing the BAD BH3 peptide to small constrained α-helices with improved ligand efficiency

Nicholas E. Shepperd, Rosemary S. Harrison, Gloria Ruiz-Gomez, Giovanni Abbenante, Jody M. Mason, David P. Fairlie

Research output: Contribution to journalArticle

8 Citations (Scopus)
85 Downloads (Pure)

Abstract

Bcl2 Homology (BH) proteins can either trigger or prevent programmed cell death or apoptosis. Deregulation of the BH protein family network leads to evasion of apoptosis, uncontrolled proliferation and is a hallmark of cancer. Inhibition of pro-survival BH proteins is a promising chemotherapeutic strategy for certain cancers. We have examined whether helix-constrained peptides based on the BAD BH3 domain (residues 103–127) can be downsized to much smaller more drug-like peptides. We report the preparation, structural characterisation, in vitro Bcl-xL inhibition and leukemic T-cell killing ability of 45 linear, mono-, bi- and tricyclic helical peptidomimetics between 8- and 19-residues in length. We show that the BAD BH3 can be downsized to 8–14 residues and still maintain appreciable affinity for Bcl-xL. In addition, the binding efficiency indices (BEI) of the downsized mimetics are significantly higher than the BAD BH3 and similar stapled BH3 mimetics, approaching drug-like molecules. This suggests that bicyclic and monocyclic mimetics based on BH3 domains are much more efficient binding ligands than the longer peptides which they mimic.
Original languageEnglish
Pages (from-to)10939-10945
JournalOrganic & Biomolecular Chemistry
Volume14
Issue number46
DOIs
Publication statusPublished - 14 Dec 2016

Fingerprint

Ligands
Peptides
Apoptosis
Peptidomimetics
Proteins
Deregulation
T-cells
Cell death
Pharmaceutical Preparations
Molecules
Bax protein (53-86)

Cite this

Downsizing the BAD BH3 peptide to small constrained α-helices with improved ligand efficiency. / Shepperd, Nicholas E.; Harrison, Rosemary S.; Ruiz-Gomez, Gloria; Abbenante, Giovanni; Mason, Jody M.; Fairlie, David P.

In: Organic & Biomolecular Chemistry, Vol. 14, No. 46, 14.12.2016, p. 10939-10945.

Research output: Contribution to journalArticle

Shepperd, NE, Harrison, RS, Ruiz-Gomez, G, Abbenante, G, Mason, JM & Fairlie, DP 2016, 'Downsizing the BAD BH3 peptide to small constrained α-helices with improved ligand efficiency', Organic & Biomolecular Chemistry, vol. 14, no. 46, pp. 10939-10945. https://doi.org/10.1039/c6ob02185a
Shepperd, Nicholas E. ; Harrison, Rosemary S. ; Ruiz-Gomez, Gloria ; Abbenante, Giovanni ; Mason, Jody M. ; Fairlie, David P. / Downsizing the BAD BH3 peptide to small constrained α-helices with improved ligand efficiency. In: Organic & Biomolecular Chemistry. 2016 ; Vol. 14, No. 46. pp. 10939-10945.
@article{98f02094c0c64101ae9e4179ebfcbf4d,
title = "Downsizing the BAD BH3 peptide to small constrained α-helices with improved ligand efficiency",
abstract = "Bcl2 Homology (BH) proteins can either trigger or prevent programmed cell death or apoptosis. Deregulation of the BH protein family network leads to evasion of apoptosis, uncontrolled proliferation and is a hallmark of cancer. Inhibition of pro-survival BH proteins is a promising chemotherapeutic strategy for certain cancers. We have examined whether helix-constrained peptides based on the BAD BH3 domain (residues 103–127) can be downsized to much smaller more drug-like peptides. We report the preparation, structural characterisation, in vitro Bcl-xL inhibition and leukemic T-cell killing ability of 45 linear, mono-, bi- and tricyclic helical peptidomimetics between 8- and 19-residues in length. We show that the BAD BH3 can be downsized to 8–14 residues and still maintain appreciable affinity for Bcl-xL. In addition, the binding efficiency indices (BEI) of the downsized mimetics are significantly higher than the BAD BH3 and similar stapled BH3 mimetics, approaching drug-like molecules. This suggests that bicyclic and monocyclic mimetics based on BH3 domains are much more efficient binding ligands than the longer peptides which they mimic.",
author = "Shepperd, {Nicholas E.} and Harrison, {Rosemary S.} and Gloria Ruiz-Gomez and Giovanni Abbenante and Mason, {Jody M.} and Fairlie, {David P.}",
year = "2016",
month = "12",
day = "14",
doi = "10.1039/c6ob02185a",
language = "English",
volume = "14",
pages = "10939--10945",
journal = "Organic & Biomolecular Chemistry",
number = "46",

}

TY - JOUR

T1 - Downsizing the BAD BH3 peptide to small constrained α-helices with improved ligand efficiency

AU - Shepperd, Nicholas E.

AU - Harrison, Rosemary S.

AU - Ruiz-Gomez, Gloria

AU - Abbenante, Giovanni

AU - Mason, Jody M.

AU - Fairlie, David P.

PY - 2016/12/14

Y1 - 2016/12/14

N2 - Bcl2 Homology (BH) proteins can either trigger or prevent programmed cell death or apoptosis. Deregulation of the BH protein family network leads to evasion of apoptosis, uncontrolled proliferation and is a hallmark of cancer. Inhibition of pro-survival BH proteins is a promising chemotherapeutic strategy for certain cancers. We have examined whether helix-constrained peptides based on the BAD BH3 domain (residues 103–127) can be downsized to much smaller more drug-like peptides. We report the preparation, structural characterisation, in vitro Bcl-xL inhibition and leukemic T-cell killing ability of 45 linear, mono-, bi- and tricyclic helical peptidomimetics between 8- and 19-residues in length. We show that the BAD BH3 can be downsized to 8–14 residues and still maintain appreciable affinity for Bcl-xL. In addition, the binding efficiency indices (BEI) of the downsized mimetics are significantly higher than the BAD BH3 and similar stapled BH3 mimetics, approaching drug-like molecules. This suggests that bicyclic and monocyclic mimetics based on BH3 domains are much more efficient binding ligands than the longer peptides which they mimic.

AB - Bcl2 Homology (BH) proteins can either trigger or prevent programmed cell death or apoptosis. Deregulation of the BH protein family network leads to evasion of apoptosis, uncontrolled proliferation and is a hallmark of cancer. Inhibition of pro-survival BH proteins is a promising chemotherapeutic strategy for certain cancers. We have examined whether helix-constrained peptides based on the BAD BH3 domain (residues 103–127) can be downsized to much smaller more drug-like peptides. We report the preparation, structural characterisation, in vitro Bcl-xL inhibition and leukemic T-cell killing ability of 45 linear, mono-, bi- and tricyclic helical peptidomimetics between 8- and 19-residues in length. We show that the BAD BH3 can be downsized to 8–14 residues and still maintain appreciable affinity for Bcl-xL. In addition, the binding efficiency indices (BEI) of the downsized mimetics are significantly higher than the BAD BH3 and similar stapled BH3 mimetics, approaching drug-like molecules. This suggests that bicyclic and monocyclic mimetics based on BH3 domains are much more efficient binding ligands than the longer peptides which they mimic.

UR - http://dx.doi.org/10.1039/c6ob02185a

U2 - 10.1039/c6ob02185a

DO - 10.1039/c6ob02185a

M3 - Article

VL - 14

SP - 10939

EP - 10945

JO - Organic & Biomolecular Chemistry

JF - Organic & Biomolecular Chemistry

IS - 46

ER -